Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Invested Capital (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Invested Capital for 10 consecutive years, with $277.2 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 40.16% to $277.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $277.2 million through Dec 2025, down 40.16% year-over-year, with the annual reading at $277.2 million for FY2025, 40.16% down from the prior year.
  • Invested Capital hit $277.2 million in Q4 2025 for Rocket Pharmaceuticals, down from $313.7 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $541.1 million in Q3 2023 to a low of $277.2 million in Q4 2025.
  • Historically, Invested Capital has averaged $422.2 million across 5 years, with a median of $429.6 million in 2022.
  • Biggest five-year swings in Invested Capital: soared 100.82% in 2021 and later tumbled 40.16% in 2025.
  • Year by year, Invested Capital stood at $454.7 million in 2021, then increased by 7.69% to $489.7 million in 2022, then grew by 0.59% to $492.6 million in 2023, then dropped by 5.96% to $463.2 million in 2024, then crashed by 40.16% to $277.2 million in 2025.
  • Business Quant data shows Invested Capital for RCKT at $277.2 million in Q4 2025, $313.7 million in Q3 2025, and $354.2 million in Q2 2025.